ArticleJPRAS open2026
Perioperative tranexamic acid in abdominally based free-flap breast reconstruction: A single-surgeon retrospective series.
Article in JPRAS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tranexamic acid reduces perioperative bleeding in many surgical settings, but its safety in microvascular breast reconstruction remains incompletely defined given theoretical concerns for anastomotic thrombosis. We evaluated outcomes after routine perioperative tranexamic acid in abdominally based free-flap breast reconstruction and contextualized findings with the evolving microsurgical literature. Materials/Patients and Methods: A retrospective review was performed of consecutive patients undergoing abdominally based deep inferior epigastric perforator free-flap breast reconstruction by a single surgeon after adoption of routine tranexamic acid (February-December 2025). All included patients received 1 g intravenous tranexamic acid at anesthesia induction and an additional 1 g at closing. Primary outcomes included hematoma, flap thrombosis, venous thromboembolism, and transfusion. Secondary outcomes included wound complications, inpatient complications, and length of stay. Results: Seventy-one reconstructions were performed in 46 patients (46 unilateral, 25 bilateral) with median follow-up of 6 months. Flap survival was 100% with no inpatient complications. No hematomas, flap thrombosis events, or transfusions occurred. Delayed complications occurred in 9 patients (19.6%), most commonly donor-site wound healing (8.7%) and skin-paddle healing (4.3%). Two patients (4.3%) required interventional radiology drainage for an abscess and seroma, and one patient experienced a segmental pulmonary embolism. Conclusions: In this single-surgeon series, perioperative tranexamic acid use during free flap breast reconstruction was safe and not associated with thrombotic or bleeding-related complications. Combined with the limited existing literature, these findings support tranexamic acid as a safe adjunct in microvascular breast reconstruction. Larger, multicenter prospective trials are needed to validate tranexamic acid's role in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.